OIA response: decision process for funding criteria for teriparatide (Forteo)
Request for information relating to how PHARMAC decided on the funding criteria for teriparatide (Forteo).
12 October 2020
Dear [name and contact details redacted]
REQUEST FOR INFORMATION
Thank you for your request dated 15 September 2020 under the Official Information Act 1982 (OIA) for information relating to how PHARMAC decided on the funding criteria for teriparatide (Forteo).
Funding of teriparatide under Section B of the Pharmaceutical Schedule is subject to the Special Authority (SA) prerequisites (funding criteria), effective 1 July 2011, as outlined in form SA1139(external link).
The SA prerequisites for teriparatide were recommended to PHARMAC by the Osteoporosis Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) and by PTAC. A public consultation was then conducted prior to the prerequisites being confirmed and finalised.
Please refer to the below documents for more information about the advice provided to PHARMAC regarding the teriparatide funding prerequisites:
- Appendix 1: PTAC and Osteoporosis Subcommittee minutes for teriparatide (parathyroid hormone) [PDF, 42 KB]
- Consultation letter dated 5 April 2011 [PDF, 144 KB]
- Notification letter dated 8 June 2011 [PDF, 135 KB]
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Manager, Policy and Government Services